Fig 6
Post-hoc analysis of fatal, serious and cardiac AEs in patients receiving tiotropium Respimat® 5 μg and tiotropium HandiHaler® 18 μg and experiencing recent serious cardiac events during TIOSPIR® [41]. Events were counted from the day following the initial cardiac event through drug stop +30 days. FAEs, fatal adverse events; MACE, major adverse cardiovascular events; NS, not significant; SAEs, serious adverse events; TIOSPIR®, Tiotropium Safety and Performance in Respimat®